ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

Liu, Diankun; Zhou, Zhanmei; Wang, Mengyi; Nie, Sheng; Li, Jun; Hu, Bianxiang; He, Wenjuan; Wang, Guobao*; Ai, Jun*南方医科大学
BMC Nephrology2021-7-1DOI: 10.1186/s12882-021-02437-4
11阅读
引用收藏
分享

摘要

Background Minimal change disease is a common cause of nephrotic syndrome in adults. Higher relapse rate put patients at risk of steroids toxicity due to long-term exposure. Rituximab has been suggested to maintain long time remission and withdraw steroids and other immunosuppressants with fewer adverse events. However, optimal dose and dosing interval have not been explored. Methods Twenty-five patients were enrolled from 2017-10 to 2020-03 in Nanfang Hospital in China. Clinical and biological data were extracted from medical records and laboratory databases. Therapy composed of 375mg/m(2) rituximab once three weeks for 3 dose and corticosteroid was applied. Complete remission was defined as reduction of proteinuria to 0.3g/d. Remission rate, relapse rate, steroids used before and after rituximab therapy and adverse effects were documented at a mean time of 14.71 months. Results Twenty-two patients achieved complete remission for an average of 3.26 months and only 3 patients experienced one relapse respectively during the follow-up period. The mean remission maintenance time was 11.6 months, and was 5 months after steroids withdrawal. Steroids dose at last follow-up was 6.09mg/d, which was significantly reduced compared to 28.15mg/d before rituximab. Relapse rate before and after rituximab was 1.43 and 0.1, respectively. Only four minor adverse events were recorded. Conclusions Therapy consisted of 375mg/m(2) rituximab once three weeks for 3 dose combined with corticosteroid is effective in inducing remission in adult patients with minimal change disease. Both of the relapse rate and dose of steroids used are significantly decreased with fewer side effects.

学科与关键词

关键词
RituximabMinimal change diseaseAdultSteroids
相关
加载中…
  • Rituximab therapy in adults with steroid-dependent nephrotic syndrome
    Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Weng, WenjuanArchives of Medical Science, 2023, 19(3): 577-585.
  • Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis
    You, Lu; Ye, Peiyi; Xiao, Guanqing; Liang, Jiabao; Kong, Yaozhong*Turkish Journal Of Medical Sciences, 2021, 51(6): 2870-2880.被引 2
  • Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
    Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Zhong, ZhiqingArchives of Medical Science, 2023, 19(2): 411-419.
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC Nephrology
发表日期
2021-07-01
卷期
第 22 卷, 第 1 期
页码
242
DOI
10.1186/s12882-021-02437-4
语言
ENGLISH
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Nature Science Foundation of China [81870489, 81770765]; President Foundation of Nanfang Hospital, Southern Medical University [2018C030]

作者

  • L

    Liu, Diankun (第一作者)

    southern med univ

  • Z

    Zhou, Zhanmei

    southern med univ

查看全部 9 位作者收起作者
  • W

    Wang, Mengyi

    southern med univ

  • N

    Nie, Sheng

    southern med univ

  • L

    Li, Jun

    southern med univ

  • H

    Hu, Bianxiang

    southern med univ

  • H

    He, Wenjuan

    southern med univ

  • W

    Wang, Guobao (通讯)

    southern med univ

  • A

    Ai, Jun (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417